Subvenções e apoios para entidades sociais

Accelerating uptake through open proposals for advanced SME innovation

União Europeia · EU

Accelerating uptake through open proposals for advanced SME innovation

Período: 5/5/2027 – —

Open grounds for future pre-commercial procurement of innovative security technologies

União Europeia · EU

Open grounds for future pre-commercial procurement of innovative security technologies

Período: 5/5/2027 – —

Demand-led innovation in security

União Europeia · EU

Demand-led innovation in security

Período: 5/5/2027 – —

Key enabling technologies for fusion power plants (European Partnership on Fusion Energy)

União Europeia · EU

Key enabling technologies for fusion power plants (European Partnership on Fusion Energy)

Período: 15/4/2027 – —

HORIZON EUROPE - Sécurité civile pour la société 2027 - 2027

França · FR

Quem pode candidatar-se Commune · Intercommunalité / Pays · Département · Région · Collectivité d’outre-mer à statut particulier · Etablissement public dont services de l'Etat · Entreprise publique locale (Sem, Spl, SemOp)

Horizon Europe - 2021-2027;Horizon Europe - Pilier 2 - Problématiques mondiales et compétitivité industrielle - 2021-2027 ----- 129,50 millions d'euros ----- Budget total de l'appel : 129,50 millions d'euros Budget par topic : HORIZON-CL3-2027-01-FCT-01 : 7,83 millions d'euros HORIZON-CL3-2027-01-FCT-02 : 6 millions d'euros HORIZON-CL3-2027-01-FCT-03 : 6 millions d'euros HORIZON-CL3-2027-01-FCT-04 : 9 millions d'euros HORIZON-CL3-2027-01-FCT-05 : 8 millions d'euros HORIZON-CL3-2027-01-BM-01 : 8 millions d'euros HORIZON-CL3-2027-01-BM-02 : 8 millions d'euros HORIZON-CL3-2027-01-BM-03 : 14 millions d'euros HORIZON-CL3-2027-01-INFRA-01 : 12 millions d'euros HORIZON-CL3-2027-01-INFRA-02 : 7,67 millions d'euros HORIZON-CL3-2027-01-DRS-01 : 7,67 millions d'euros HORIZON-CL3-2027-01-DRS-02 : 6 millions d'euros HORIZON-CL3-2027-01-DRS-03 : 9 millions d'euros HORIZON-CL3-2027-01-DRS-04 : 8 millions d'euros HORIZON-CL3-2027-01-SSRI-01 : 4,5 millions d'euros HORIZON-CL3-2027-01-SSRI-02 : 2 millions d'euros HORIZON-CL3-2027-01-SSRI-03 : 5,83 millions d'euros Montant de la subvention : entre 1 et 7,833 millions d'euros ----- Certains financements au titre du programme Horizon Europe sont structurés en réponse à des ambitions politiques (« destinations ») et déployés à travers des appels à propositions (« Calls for proposals ») ciblant des thématiques ou secteurs plus précis (« Topics »). Ainsi, votre candidature doit être directement reliée à un topic d’un appel à propositions. Différentes catégories de projets sont éligibles : RIA, Research and Innovation Actions : Recherche basique et appliquée / Développement et adoption de technologies / Essai et validation d'un prototype en laboratoire ; IA, Innovation Actions : Prototypes, tests, démonstrations, projets pilotes, placement sur le marché. Ces actions peuvent inclure un volet limité aux activités de R&D ; CSA, Coordination and Support Actions : Réseautage, études & conférences, communication, études pour de nouvelles infrastructures de recherche ; MSCA, Marie Skłodowska-Curie Actions / Bourses ERC : Réseaux de formation pour les chercheurs, Bourses individuelles pour les chercheurs expérimentés, Echange de personnels – mobilité pour les chercheurs et le personnel non scientifique. De même, les appels précisent les bénéficiaires attendus : Projets collaboratifs, composés d’un coordinateur et des partenaires (consortium) ; Projets mono-bénéficiaires, impliquant une seule organisation ; Bourses individuelles, ouvertes à des personnes physiques en leur nom propre avec leur établissement de rattachement. TOPICS : A venir HORIZON-CL3-2027-01-FCT-01: Outils de détection et d’investigation des préjudices en ligne utilisant un modèle de cycle de développement court HORIZON-CL3-2027-01-FCT-02: Police de proximité dans des sociétés européennes diversifiées HORIZON-CL3-2027-01-FCT-03: Sujet ouvert sur le renforcement de la prévention, de la détection et de la dissuasion des problématiques sociétales liées aux différentes formes de criminalité HORIZON-CL3-2027-01-FCT-04: Sujet ouvert sur le renforcement de la sécurité des citoyens face au terrorisme, y compris dans les espaces publics HORIZON-CL3-2027-01-FCT-05: Réponses efficaces et fondées sur des preuves face à la disponibilité et à l’usage accrus de drogues synthétiques et de stimulants en Europe HORIZON-CL3-2027-01-BM-01: Sujet ouvert sur la recherche et l’innovation pour une gestion efficace des frontières extérieures de l’UE, favorisant les droits fondamentaux et les valeurs de l’Union HORIZON-CL3-2027-01-BM-02: Titres de voyage numériques futurs fiables, sécurisés et de haute qualité HORIZON-CL3-2027-01-BM-03: Détection et caractérisation des menaces ou des marchandises illégales / de contrebande dans le fret HORIZON-CL3-2027-01-INFRA-01: Renforcement de la protection physique des infrastructures critiques HORIZON-CL3-2027-01-INFRA-02: Impact de l’utilisation malveillante du renseignement en sources ouvertes (OSINT) sur la continuité des activités des infrastructures critiques HORIZON-CL3-2027-01-DRS-01: Sujet ouvert sur des équipements de protection avancés optimisés pour les environnements CBRN-E (chimiques, biologiques, radiologiques, nucléaires et explosifs) et une nouvelle génération d’équipements de protection intelligents pour les intervenants en situation de catastrophe HORIZON-CL3-2027-01-DRS-02: Résilience sociétale, engagement des jeunes générations et innovation numérique pour la résilience face aux catastrophes HORIZON-CL3-2027-01-DRS-03: Amélioration des systèmes d’aide à la décision pour les crises de catastrophe : exploitation des technologies émergentes pour une meilleure préparation civile et une gestion de crise renforcée HORIZON-CL3-2027-01-DRS-04: Renforcement de la préparation aux catastrophes transfrontalières de grande ampleur HORIZON-CL3-2027-01-SSRI-01: Accélération de l’adoption par des propositions ouvertes en faveur de l’innovation avancée des PME HORIZON-CL3-2027-01-SSRI-02: Bases ouvertes pour de futurs marchés publics avant commercialisation de technologies de sécurité innovantes HORIZON-CL3-2027-01-SSRI-03: Innovation en matière de sécurité tirée par la demande Informations complémentaires Pour trouver votre Point de Contact National (NCP) : Cliquez ici Utile Lignes directrices (EN) : Cliquez ici Autres documents de l’appel (EN) : Cliquez ici Site web de la DG (EN) : Cliquez ici Plus d’informations (EN): Cliquez ici

Período: 5/5/2027 – —

Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)

Estados Unidos · US

Quem pode candidatar-se Others (see text field entitled "Additional Information on Eligibility" for clarification) · Special district governments · Native American tribal governments (Federally recognized) · Native American tribal organizations (other than Federally recognized tribal governments) · County governments · Private institutions of higher education · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · For profit organizations other than small businesses · City or township governments · State governments · Public and State controlled institutions of higher education · Public housing authorities/Indian housing authorities · Small businesses · Independent school districts

This Notice of Funding Opportunity (NOFO) seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that align with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities were most recently described in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.

Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)

Estados Unidos · US

Quem pode candidatar-se Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · For profit organizations other than small businesses · Independent school districts · Special district governments · City or township governments · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Native American tribal governments (Federally recognized) · Public housing authorities/Indian housing authorities · State governments · Small businesses · Native American tribal organizations (other than Federally recognized tribal governments) · Public and State controlled institutions of higher education · Private institutions of higher education · County governments · Others (see text field entitled "Additional Information on Eligibility" for clarification)

The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); efficacy in animal models; development of biomarkers for target engagement; formulation development; chemical synthesis under Good Manufacturing Practices (GMP); Investigational New Drug (IND) enabling studies; and initial Phase I clinical testing. Applications not responsive to this NOFO include research on basic mechanisms of disease or mechanisms of drug action; development ofrisk, diagnostic, prognostic, predictive, and preventionbiomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combination therapies; discovery activities such as high-throughput screening and hit optimization; and stand-alone clinical trials.

Limited Competition: Renewal of Existing NINDS-Supported Clinical Trial Cooperative Agreement Awards (U01 - Clinical Trials Required)

Estados Unidos · US

Quem pode candidatar-se Independent school districts · Public housing authorities/Indian housing authorities · Others (see text field entitled "Additional Information on Eligibility" for clarification)

This limited competition Notice of Funding Opportunity (NOFO) invites renewal applications of existing NINDS-supported clinical trial cooperative agreement awards (U01) requiring additional time and resources to complete the clinical trial.

BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed)

Estados Unidos · US

Quem pode candidatar-se State governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Independent school districts · City or township governments · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Special district governments · Private institutions of higher education · For profit organizations other than small businesses · Public and State controlled institutions of higher education · Public housing authorities/Indian housing authorities · Small businesses · County governments · Native American tribal governments (Federally recognized) · Native American tribal organizations (other than Federally recognized tribal governments) · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education

The Theories, Models and Methods (TMM) initiative will support the development of computational tools for understanding dynamic brain circuits that are made broadly accessible to the greater research community. This program supports applications focused on tool building and dissemination in the domain of theories about neural circuit mechanisms, models of circuit structure and function, and/or computational methods of analysis spanning across scales from neurons to behavior. The development of novel theories, computational models and methods for understanding brain function will help characterize fundamental principles of brain function and organization, characterize cellular and circuit-level neural computations over time in different regions, and understand how interactions of multiple brain circuits enable flexible behaviors and contribute to brain-wide neural dynamics. These tools will be critical for developing treatments such as closed loop systems for brain disorders including Parkinsons disease and major depressive disorder.

Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Required)

Estados Unidos · US

Quem pode candidatar-se Independent school districts · Private institutions of higher education · City or township governments · Native American tribal governments (Federally recognized) · Native American tribal organizations (other than Federally recognized tribal governments) · County governments · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Public housing authorities/Indian housing authorities · Special district governments · State governments · For profit organizations other than small businesses · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Small businesses · Public and State controlled institutions of higher education · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education

The objective of the NIH Career Transition Award (K22) is to provide support to outstanding basic or clinical investigators to develop their independent research skills through a two phase program: an initial period involving an intramural appointment at the NIH and a final period of support at an extramural institution. This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities.

Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Not Allowed)

Estados Unidos · US

Quem pode candidatar-se County governments · State governments · Native American tribal organizations (other than Federally recognized tribal governments) · Small businesses · Native American tribal governments (Federally recognized) · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Private institutions of higher education · Public and State controlled institutions of higher education · Public housing authorities/Indian housing authorities · Others (see text field entitled "Additional Information on Eligibility" for clarification) · For profit organizations other than small businesses · Independent school districts · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · City or township governments · Special district governments

The objective of the NIH Career Transition Award (K22) is to provide support to outstanding basic or clinical investigators to develop their independent research skills through a two phase program: an initial period involving an intramural appointment at the NIH and a final period of support at an extramural institution. This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities.

NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)

Estados Unidos · US

Quem pode candidatar-se Public and State controlled institutions of higher education · County governments · Native American tribal organizations (other than Federally recognized tribal governments) · Private institutions of higher education · Small businesses · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Public housing authorities/Indian housing authorities · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · For profit organizations other than small businesses · State governments · Independent school districts · Native American tribal governments (Federally recognized) · City or township governments · Special district governments

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIDA R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. This NOFO is intended to support research education activities that enhance the knowledge of substance use and substance use disorder research. The program is intended for those in clinically focused careers and/or those training for careers as clinicians/health service providers, clinical researchers, or optimally a combination of the two. This mechanism may not be used to support non-research-related clinical training.

NIA Academic Leadership Career Award (K07 Independent Clinical Trial Not Allowed)

Estados Unidos · US

Quem pode candidatar-se Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Independent school districts · Private institutions of higher education · Small businesses · City or township governments · Special district governments · Native American tribal organizations (other than Federally recognized tribal governments) · State governments · For profit organizations other than small businesses · Native American tribal governments (Federally recognized) · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Public and State controlled institutions of higher education · Public housing authorities/Indian housing authorities · Others (see text field entitled "Additional Information on Eligibility" for clarification) · County governments

The objective of the NIA Academic Leadership Career Award (K07) is to provide support for established investigators who have the expertise and leadership skills to enhance aging and/or Alzheimer's Disease (AD) and Alzheimers Disease Related Dementias (ADRD)research capacity within their academic institution. Through this award, investigators will endeavor to develop research and educational infrastructure, mentorship, and career development activities in support of new or emerging areas of aging and/or AD/ADRDresearch. These may include, but are not limited to, courses, curricula, research support, pilot funding, travel awards, visiting scholars, or networks. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator.

Subvenciones natalidad

LOCAL - PERDIGUERA - AYUNTAMIENTO DE PERDIGUERA ·

Servicios Sociales y Promoción Social

Leveraging Network Infrastructure to Conduct Innovative Research for Women, Children, Pregnant and Lactating Women, and Persons with Disabilities (UG3/UH3 - Clinical Trial Optional)

Estados Unidos · US

Quem pode candidatar-se City or township governments · Private institutions of higher education · Public housing authorities/Indian housing authorities · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · State governments · Native American tribal governments (Federally recognized) · Small businesses · Special district governments · Native American tribal organizations (other than Federally recognized tribal governments) · County governments · Independent school districts · Public and State controlled institutions of higher education · For profit organizations other than small businesses

The purpose of this Notice of Funding Opportunity (NOFO) is to leverage NICHD clinical research Network infrastructure relevant to infants, children, women, pregnant and lactating women, and persons with disabilities to conduct innovative, multisite, investigator-initiated clinical trials and observational studies. This NOFO will utilize a bi-phasic (UG3/UH3), milestone-driven mechanism consisting of a start-up phase (UG3) and a full enrollment and clinical trial implementation phase (UH3). Applications submitted in response to this NOFO must address specific aims and milestones for both the UG3 and UH3 phases. A UG3 project (phase I) that meets its milestones will be administratively considered by NICHD and prioritized for transition to the UH3 award (phase II). This NOFO provides an opportunity to leverage NICHD clinical research Network infrastructure as a platform for investigator-initiated innovative hypotheses by any investigator in the extramural community. Applications must be submitted as investigator-initiated, multi-Project Director/Principal Investigator (PD/PI) grant applications in conjunction with the respective NICHD-supported Network Data Coordinating Center (DCC), or equivalent as determined by the NICHD.

Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)

Estados Unidos · US

Quem pode candidatar-se Special district governments · Private institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Native American tribal governments (Federally recognized) · County governments · Independent school districts · Public and State controlled institutions of higher education · Public housing authorities/Indian housing authorities · City or township governments · State governments · Small businesses · Native American tribal organizations (other than Federally recognized tribal governments) · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · For profit organizations other than small businesses

Through this Notice of Funding Opportunity (NOFO), entitled "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI), the National Cancer Institute (NCI) encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. TTNCI awards are designed to mature experimental nanomedicines relying on nanoparticles and nano-devices which demonstrate strong potential to improve cancer treatment effectiveness due to the combination of nanoparticle/nano-device structural design and/or therapeutic/diagnostic cargo which is delivered. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.

Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed)

Estados Unidos · US

Quem pode candidatar-se Native American tribal governments (Federally recognized) · State governments · Public and State controlled institutions of higher education · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Private institutions of higher education · Special district governments · Native American tribal organizations (other than Federally recognized tribal governments) · City or township governments · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · County governments · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Independent school districts · Public housing authorities/Indian housing authorities · For profit organizations other than small businesses · Small businesses

This Notice of Funding Opportunity (NOFO) invites applications for innovative basic and translational pilot research projects within the mission of the NIDDK that are aligned with NIH HIV/AIDS research priorities. These priorities were most recently outlined by the NIH Office of AIDS Research (OAR) in NOT-20-018, UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding, scientific priorities. Potential topics could address multiple overarching priorities. These include elucidation of unique pathophysiological mechanisms contributing to HIV comorbidities, coinfections, and complications (CCCs) affecting organs, tissues, and processes within the mission of the NIDDK. Likewise, interrogations into biological mechanisms underlying HIV reservoirs in NIDDK-relevant tissues are important for developing strategies for long-term viral suppression or eradication. Finally, health-impeding social determinants of health may affect CCCs or viral reservoirs within NIDDK's mission through multiple pathways.

Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)

Estados Unidos · US

Quem pode candidatar-se State governments · Native American tribal governments (Federally recognized) · County governments · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Public and State controlled institutions of higher education · Private institutions of higher education · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Native American tribal organizations (other than Federally recognized tribal governments) · Small businesses · Special district governments · Public housing authorities/Indian housing authorities · For profit organizations other than small businesses · City or township governments · Independent school districts · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education

This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future.Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.

Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)

Estados Unidos · US

Quem pode candidatar-se Independent school districts · Special district governments · Private institutions of higher education · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Native American tribal governments (Federally recognized) · Public housing authorities/Indian housing authorities · Native American tribal organizations (other than Federally recognized tribal governments) · County governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification) · State governments · Public and State controlled institutions of higher education · For profit organizations other than small businesses · City or township governments · Small businesses

This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future.Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.

Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)

Estados Unidos · US

Quem pode candidatar-se Private institutions of higher education · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Public housing authorities/Indian housing authorities · State governments · Independent school districts · Public and State controlled institutions of higher education · Small businesses · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification) · County governments · City or township governments · For profit organizations other than small businesses · Native American tribal governments (Federally recognized) · Native American tribal organizations (other than Federally recognized tribal governments) · Special district governments

This Notice of Funding Opportunity (NOFO) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants will support innovative studies designed to investigate biological/genetic bases of cancer health disparities, such as (1) mechanistic studies of biological factors associated with cancer health disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This NOFO is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.

Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed)

Estados Unidos · US

Quem pode candidatar-se Public housing authorities/Indian housing authorities · State governments · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification) · County governments · Public and State controlled institutions of higher education · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Independent school districts · For profit organizations other than small businesses · City or township governments · Native American tribal governments (Federally recognized) · Private institutions of higher education · Native American tribal organizations (other than Federally recognized tribal governments) · Small businesses · Special district governments

The purpose of this notice of funding opportunity (NOFO) is to solicit applications for pilot projects to elucidate a role for understudied proteins in rare disease. Awards will support generation of preliminary data and/or tools around eligible understudied protein(s). A list of eligible proteins is provided and are members of druggable protein families that have a known association with a rare disease. This NOFO is intended to jumpstart research on understudied proteins that are associated with rare diseases and provide applicants with sufficient funding to perform basic biochemical and/or biological work to further the characterization of understudied proteins within the context of rare disease.

EIC Pre-accelerator - Widening

União Europeia · EU

EIC Pre-accelerator - Widening

Período: 5/5/2027 – —

Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)

Estados Unidos · US

Quem pode candidatar-se Small businesses · State governments · Public and State controlled institutions of higher education · Native American tribal governments (Federally recognized) · Public housing authorities/Indian housing authorities · Independent school districts · For profit organizations other than small businesses · Native American tribal organizations (other than Federally recognized tribal governments) · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · City or township governments · Others (see text field entitled "Additional Information on Eligibility" for clarification) · County governments · Private institutions of higher education · Special district governments

This notice of funding opportunity (NOFO) will support research towards understanding and mitigating the deleterious effects of acute exposure to Ultra-Potent Synthetic (UPS) opioids (e.g., fentanyl, carfentanil, nitazenes) and their combinations (fentanyl and xylazine). This NOFO will also support research on the persistent and/or delayed pathophysiological effects after acute exposure to such agents.

DEVCOM ARMY RESEARCH LABORATORY BROAD AGENCY ANNOUNCEMENT FOR FOUNDATIONAL RESEARCH

Estados Unidos · US

Quem pode candidatar-se Others (see text field entitled "Additional Information on Eligibility" for clarification)

The purpose of this combined Broad Agency Announcement (BAA) under Federal Acquisition Regulation (FAR) Part 35 and Funding Opportunity Announcement (FOA) under 2 Code of Federal Regulations (CFR) 200.204 (henceforth referred to as “BAA”) is to solicit research proposals for submission to the U.S. Army Combat Capabilities Development Command (DEVCOM) Army Research Laboratory (ARL) for funding consideration. Prior to this announcement, ARL announced two separate BAAs to support the mission: 1) W911NF-17-S-0002 titled “Army Research Laboratory Army Research Office Broad Agency Announcement for Fundamental Research”; and 2) W911NF-17-S-0003 titled “Army Research Laboratory Broad Agency Announcement for Basic and Applied Scientific Research”. This announcement succeeds BAA W911NF-17-S-0002 and BAA W911NF-17-S-0003 combining the opportunities into a single announcement. ARL’s mission as the Army’s foundational research laboratory is to Operationalize Science to ensure overmatch in any future conflict. ARL’s foundational research mission spans basic research (budget activity 6.1) and applied research (budget activity 6.2) as defined by 32 CFR 22.105 but may include advanced technology development (budget activity 6.3) and advanced component development and prototypes (budget activity 6.4) when opportunities arise to directly or indirectly help achieve ARL’s mission. ARL partners across the national security enterprise to deliver fundamentally advantageous change that is rooted in the creation and exploitation of scientific knowledge. This publication constitutes a BAA for awards as contemplated in FAR 6.102(d)(2) and 35.016 as well as a merit-based, competitive procedure in accordance with the Department of Defense Grant and Agreement Regulations (DoDGARS) at 32 CFR 22.315(a) and the Office of the Under Secretary of Defense for Acquisition and Sustainment Other Transaction Guide version 2.0 dated July 2023. This BAA document, and the online list of research topics found on the ARL BAA topics website at https://www.arl.devcom.army.mil/opportunities/arl-baa/ , sets forth ARL’s research topics of interest for whitepapers and proposals. This BAA is issued under FAR 6.102(d)(2), which provides for the competitive selection of basic and applied research proposals, and 10 U.S.C. 4001, 10 U.S.C. 4021, and 10 U.S.C. 4022, which provide the authorities for issuing awards under this announcement for basic and applied research. The definitions of basic and applied research may be found at 32 CFR 22.105. Proposals submitted in response to this BAA and selected for award are considered to be the result of full and open competition and in full compliance with the provision of Public Law 98-369, “The Competition in Contracting Act of 1984” and subsequent amendments.